CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Cytokinetics, Inc. common stock during the specified Class Period, alleging misleading statements regarding the New Drug Application for aficamten [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Cytokinetics, Inc. and covers stock purchases made between December 27, 2023, and May 6, 2025 [1]. - The lawsuit claims that Cytokinetics made false statements about the expected approval timeline for aficamten, specifically regarding the FDA's approval process and the failure to disclose risks related to the Risk Evaluation and Mitigation Strategy [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting Rosen Law Firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 17, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].